

**RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION/PERFORMANCE SHARES PLANS**

Milan, 11<sup>th</sup> November 2024 – Following the press release issued on 8<sup>th</sup> November 2024 related to the approval of the interim report at 30<sup>th</sup> September 2024, Recordati S.p.A. (the “Company”) informs that, in execution of the resolution adopted by the Shareholders’ meeting held on 22<sup>nd</sup> April 2024, it has granted a mandate to UBS Europe SE to launch starting from Tuesday 12<sup>th</sup> November 2024 – in full independency, in compliance with applicable legislation and the provisions of the shareholders’ meeting resolution - a share buy-back program under art. 5 of (EU) Regulation no. 596/2014 and (EU) delegated Regulation no. 1052/2016 (the “**Program**”), on behalf of the Company.

The details of the Program are the following:

- **Purpose of the Program:** the Program involves the purchase of Recordati ordinary shares to service current stock option/performance shares plans in favour of the Recordati Group’s management or share-based incentive plans that might be approved by the Company in the future.
- **Maximum number of shares:** the acquisition could involve a maximum of up to no. 1,500,000 ordinary nominal value Eur 0.125 Recordati shares and, in any case, within the legal limit (1/5 of the company’s entire share capital as established by art. 2357, paragraph 3 of the Italian Civil Code), including any shares owned by the Company.

As of 8<sup>th</sup> November 2024, the Company had no. 2,514,204 shares in treasury stock which amounts to 1.202% of the share capital.

- **Minimum and maximum consideration payable and maximum cash outlay:** the minimum purchase price for the ordinary shares shall not be lower than the share’s nominal value (Eur 0.125) while the maximum purchase price shall not be greater than the average of the official Stock Exchange prices in the 5 sessions prior to the purchase, plus 5%, within the maximum cash outlay of Eur 90 million (ninety million).
- **Duration:** until 15<sup>th</sup> April 2025. Please be reminded that the expiry of the authorization granted by the Shareholders’ meeting held on 22<sup>nd</sup> April 2024 is until the approval by the Shareholders’ meeting of the 2024 financial statements.
- **Buyback procedures:** in compliance with art. 132 of the Legislative Decree 58/1998 and art. 144-bis, paragraph 1, letter b) of the Issuers Regulation, as well as in compliance with (EU) Regulation 596/2014 of 16<sup>th</sup> April 2014 and its relative implementing provisions (also with reference to the purchase price and the daily volume allowed) and in line with the authorization of the Shareholders’ Meeting.

Any subsequent changes to the programme will be promptly disclosed to the public according to the conditions and deadlines set forth by the applicable law.

The operations carried out will be disclosed to the market according to the deadlines and conditions set forth by the regulatory provisions currently in force.

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered Office  
Via Matteo Civitali, 1  
20148 Milano, Italy  
Tel. +39 02 487871  
Fax +39 02 40073747  
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up  
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150  
Tax Code/VAT No. 00748210150  
Milano R.E.A. No. 401832

**Recordati** is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of “unlocking the full potential of life” aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.

### **Investor Relations**

Eugenia Litz  
+44 7824 394 750  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

Gianluca Saletta  
+39 348 979 4876  
[investorelations@recordati.it](mailto:investorelations@recordati.it)

### **Media Relations**

ICR Healthcare US:  
Alexis Feinberg  
[+1 203 939 2225](tel:+12039392225)  
[recordatiuspr@westwicke.com](mailto:recordatiuspr@westwicke.com)

UK, Europe & Rest of World:  
Jessica Hodgson  
+44 7561 424 788  
[recordati@consilium-comms.com](mailto:recordati@consilium-comms.com)